Video

MSI Testing Is Crucial in Colorectal Cancer

Author(s):

Michael J. Overman, M.D.

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

Genetic testing — particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer (CRC), says Michael J. Overman, M.D., associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center.

Recent findings presented at the 2017 Gastrointestinal Cancers Symposium found that the immunotherapy agent Opdivo (nivolumab) drastically improved response rates and progression-free survival in patients with metastatic CRC who tested positive for MSI. Since the agent is so promising, it is important to identify patients who would benefit from this treatment.

Related Videos
Image of man with grey hair.
Image of woman with black hair.
Image of a smiling woman with brown hair.
Image of a woman with short brown hair, wearing glasses.
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a black button-up shirt.
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Related Content
Image of "FDA Breakthrough Therapy Designation" with a gold background.
December 21st 2024

FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

Ryan Scott
Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
"FDA" text.
December 20th 2024

FDA Approves Braftovi Plus Erbitux and Chemo for Metastatic Colorectal Cancer Subset

Darlene Dobkowski, MA
Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
Illustration of a tumor present in the rectum.
December 6th 2024

MRIs May Predict Organ Preservation, Survival in Rectal Cancer

Spencer Feldman
MRIs were able to predict organ preservation and survival with the “watch-and-wait” approach in patients with rectal cancer.
‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself
December 5th 2024

‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself

Alex Biese
Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.